Entellus Medical (ENTL) Announces Publication of Positive XprESS Balloon SDS Study Data
- Stocks decline as interest rate uncertainty, earnings weigh
- ASML slides as Q1 sales fall short but firm still on track for 2025 revenue target
- United Airlines maintains forecast after Q1 results top Wall Street estimates
- US dollar weakens as market consolidates gains, but uptrend intact
- Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- Barnes & Noble Education (BNED) Enters Definitive Agreement with Immersion (IMMR)
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
Entellus Medical Announces Publication of Positive Clinical Data for XprESS for Treatment of Pediatric Chronic Rhinosinusitis
November 29, 2016 8:47 AM ESTPLYMOUTH, Minn., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ: ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced that the results of a prospective, multicenter clinical study using the Companys XprESS balloon sinus dilation system in pediatric patients were published in the peer reviewed journal International Forum of Allergy & Rhinology.
The clinical study evaluated fifty pediatric patients suffering from chronic rhinosinusitis (CRS): 33 patients between the ages of 2 and 12... More